Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Altera
Administered By
Awarded By
Contributors
- Inman, Brant Allen Principal Investigator
Start/End
- July 14, 2020 - April 30, 2023